HK Stock Market Move | PEIJIA-B (09996) rises over 5% as several key figures in the interim report shine; the company raises its full-year TAVR implantation guidance.

PEIJIA-B (09996) rose by over 5%, and as of the time of writing, it has increased by 3.14% to HKD 5.58, with a trading volume of HKD 1.2524 million. On the news front, Peijia Medical recently disclosed its interim results, with several core metrics performing impressively. In the first half of the year, it achieved a total revenue of RMB 425 million, a year-on-year increase of 20.1%. With the combined effects of rising main business revenue and refined management, the company's profit quality continues to improve: the gross profit for the period reached RMB 290 million, a year-on-year increase of 17.1%; both EBITDA and pre-tax profit turned positive; and the net loss for the period narrowed significantly by 87.4% year-on-year to approximately RMB 8.99 million, indicating profitability is on the horizon. It is noteworthy that during the earnings conference call on August 24, Peijia's management raised the full-year guidance for the company's valve business implant volume from the previous expectation of over 5,000 units at the beginning of the year to 6,000-6,500 units. Among them, the reflux valve business is expected to have an annual implant volume of no less than 2,500 units, with a revenue growth rate exceeding 30%, demonstrating the company's strong confidence in the continued growth of this segment.